232 related articles for article (PubMed ID: 28155335)
1. Design of amphotericin B oral formulation for antifungal therapy.
Liu M; Chen M; Yang Z
Drug Deliv; 2017 Nov; 24(1):1-9. PubMed ID: 28155335
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B
Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
4. Oral bioavailability and stability study of a self-emulsifying drug delivery system (SEDDS) of amphotericin B.
Bhattacharyya A; Bajpai M
Curr Drug Deliv; 2013 Oct; 10(5):542-7. PubMed ID: 23675913
[TBL] [Abstract][Full Text] [Related]
5. Long-term sustained-released in situ gels of a water-insoluble drug amphotericin B for mycotic arthritis intra-articular administration: preparation, in vitro and in vivo evaluation.
Shan-Bin G; Yue T; Ling-Yan J
Drug Dev Ind Pharm; 2015 Apr; 41(4):573-82. PubMed ID: 24502270
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral
Zhou L; Zhang P; Chen Z; Cai S; Jing T; Fan H; Mo F; Zhang J; Lin R
Int J Nanomedicine; 2017; 12():4269-4283. PubMed ID: 28652732
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B formulations and drug targeting.
Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S
J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903
[TBL] [Abstract][Full Text] [Related]
8. Improved Oral Bioavailability and Gastrointestinal Stability of Amphotericin B through Fatty Acid Conjugation Approach.
Thanki K; Date T; Jain S
Mol Pharm; 2019 Nov; 16(11):4519-4529. PubMed ID: 31509418
[TBL] [Abstract][Full Text] [Related]
9. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.
Thornton SJ; Wasan KM
Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044
[TBL] [Abstract][Full Text] [Related]
10. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Gangadhar KN; Adhikari K; Srichana T
Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
[TBL] [Abstract][Full Text] [Related]
13. Strategies to enhance oral delivery of amphotericin B: a comparison of uncoated and enteric-coated nanostructured lipid carriers.
Nimtrakul P; Sermsappasuk P; Tiyaboonchai W
Drug Deliv; 2020 Dec; 27(1):1054-1062. PubMed ID: 32633144
[TBL] [Abstract][Full Text] [Related]
14. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
[TBL] [Abstract][Full Text] [Related]
16. Stability and transdermal absorption of topical amphotericin B liposome formulations.
Manosroi A; Kongkaneramit L; Manosroi J
Int J Pharm; 2004 Feb; 270(1-2):279-86. PubMed ID: 14726142
[TBL] [Abstract][Full Text] [Related]
17. Lipid formulation as a drug carrier for drug delivery.
Tomii Y
Curr Pharm Des; 2002; 8(6):467-74. PubMed ID: 12069383
[TBL] [Abstract][Full Text] [Related]
18. A novel formulation of solubilised amphotericin B designed for ophthalmic use.
Serrano DR; Ruiz-Saldaña HK; Molero G; Ballesteros MP; Torrado JJ
Int J Pharm; 2012 Nov; 437(1-2):80-2. PubMed ID: 22890190
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ
Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
[TBL] [Abstract][Full Text] [Related]
20. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]